Untitled
Previous | Next

Back to BW50
Home Page >>

The BusinessWeek 50 Ranking

17

Gilead Sciences

ONCE, TAMIFLU was simply the icing on the cake for Gilead Sciences, a fast-growing biotech that’s a leader in developing HIV drugs. But fears of an avian flu pandemic have led governments to begin stockpiling the antiflu drug, which Gilead invented and later licensed to Roche Holdings Ltd. Largely owing to Tamiflu, Gilead’s royalty revenues skyrocketed 166%, to $219 million, in 2005. The Foster City (Calif.) company is also trying to cement its No.1 position in its core HIV drug business. Strong sales there helped push overall revenues up 53%, to $2 billion. Profits jumped 81%, to $814 million. In the second quarter, Gilead plans to seek approval from the U.S. Food & Drug Administration for the first-ever regimen to treat HIV that would pack three drugs into one pill. That project, which Gilead is developing with Bristol-Myers Squibb Co., could hit the market by the end of the year. Analysts are so optimistic that Gilead can maintain its leadership in the antiviral market that they’re predicting the company’s earnings will grow 19% a year for the next five years.

Company Info

2005 Rank

47

GET MORE
COMPANY INFO

GILD

Market Value
$ Million

28,627.1

Total Return
$ Million
(1-yr.) 80.2
(3-yr.) 266.3
2005 Sales
$ Billion

2.0

Sales Growth
$ Million
(1-yr.) 53
(3-yr.) 62.1
Long-Term Growth Est. %

19.0

Net income
$ Million

813.9

Net Income Growth
$ Million
(1-yr.) 81
(3-yr.) 127.8
Net Margin %*

40.1

Return on Inv. Capital (%)*

24.8

Share Price
12-Mo. Hi/Lo

64/34

P/E Ratio

36

Industry Pharmaceuticals & Biotechnology
CORPORATE WEB SITE
More in S&P 500 Companies Scoreboard >
*Trailing 12 months
Company data as of 2/28/06 provided by Standard & Poor's Compustat

John C. Martin

John C. Martin, 54

CEO since 1996


PHOTO BY Mark Richards


More BW Stories on Gilead Sciences